Regulation of BileAcid Synthesis by a alpha1-AT Peptide

α1-AT 肽对胆汁酸合成的调节

基本信息

  • 批准号:
    6676635
  • 负责人:
  • 金额:
    $ 36.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-01 至 2008-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Bile acid synthesis plays a crucial role in maintaining cholesterol homeostasis since it is responsible for the catabolism of more than 50% of the cholesterol excreted from the body. High plasma cholesterol often results in atherosclerosis, which is a form of chronic inflammation. In response to inflammation, the rate of synthesis of alpha1-antitrypsin (alpha1 -AT) increases. Alpha1-antitrypsin is a serum protease inhibitor that is synthesized in the liver and its rate of synthesis increases in response to inflammation. This increase in alpha1-AT synthesis gives rise to an increase in peptides, like its carboxy-terminal C-36 peptide, resulting from alpha1-AT cleavage by proteases. Because of this correlation between plasma cholesterol levels, inflammation and alpha1-AT rate of synthesis, we investigated the effect of the C-36 serpin peptide on hepatic bile acid biosynthesis and showed that C-36 is a powerful and specific transcriptional down-regulator of bile acid synthesis through inhibition of the cholesterol 7alpha-hydroxylase/CYP7A1 (7alpha-hydroxylase) and sterol12alpha-hydroxylase/CYP8B1 (12alpha-hydroxylase) promoters. This inhibition appears to be mediated by specifically interacting with alpha1-fetoprotein transcriptional factor (FTF), a positive transcriptional factor key in bile acid biosynthesis. We hypothesize that the C-36 peptide specifically interacts with FTF, and this interaction suppresses 7alpha- and 12alpha-hydroxylase promoter activities. Experiments are proposed to validate this hypothesis and to study the molecular mechanisms involved in the interaction between these two molecules, the FTF protein and the alpha1-AT-derived C-36 peptide. The specific aims of this proposal are: 1. Determine the effect of the a1-AT derived C-36 peptide on bile acid biosynthesis in animals. 2. Determine the subcellular targeting of the alpha1-AT derived C-36 peptide in both culture cells and animals. 3. Characterization of the mechanism of action involved in the regulation of 7alpha- and 12alpha-hydroxylase gene transcription by the alpha1-AT derived C-36 peptide. 4. Characterization of the alpha1-AT promoter and its self-regulation by the C-36 peptide. The successful completion of this project may provide an important link between cholesterol homeostasis and inflammation.
描述(由申请人提供):胆汁酸合成在维持胆固醇稳态中起着至关重要的作用,因为它负责从体内排出的超过50%的胆固醇的催化。高血浆胆固醇通常导致动脉粥样硬化,这是一种慢性炎症。在炎症反应中,α 1-抗胰蛋白酶(α 1-AT)的合成速率增加。α 1-抗胰蛋白酶是一种血清蛋白酶抑制剂,在肝脏中合成,其合成速率响应于炎症而增加。这种α 1-AT合成的增加引起肽的增加,如其羧基末端C-36肽,这是由蛋白酶切割α 1-AT引起的。由于血浆胆固醇水平、炎症和α 1-AT合成率之间的这种相关性,我们研究了C-36丝氨酸蛋白酶抑制剂肽对肝胆汁酸生物合成的影响,并表明C-36通过抑制胆固醇7 α-羟化酶/CYP 7A 1,是胆汁酸合成的一种强有力的特异性转录下调剂(7 α-羟化酶)和甾醇12 α-羟化酶/CYP 8B 1(12 α-羟化酶)启动子。这种抑制作用似乎是通过与甲胎蛋白转录因子(FTF)特异性相互作用介导的,FTF是胆汁酸生物合成中的一种正性转录因子。我们假设C-36肽特异性地与FTF相互作用,并且这种相互作用抑制7 α-和12 α-羟化酶启动子活性。提出实验来验证这一假设,并研究这两个分子之间的相互作用,FTF蛋白和α 1-AT衍生的C-36肽的分子机制。该提案的具体目标是:1.确定α 1-AT衍生的C-36肽对动物中胆汁酸生物合成的影响。2.确定α 1-AT衍生的C-36肽在培养细胞和动物中的亚细胞靶向。 3.α 1-AT衍生C-36肽调节7 α-和12 α-羟化酶基因转录的作用机制表征。 4.α 1-AT启动子的表征及其通过C-36肽的自我调节。 该项目的成功完成可能提供胆固醇稳态和炎症之间的重要联系。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GREGORIO GIL其他文献

GREGORIO GIL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GREGORIO GIL', 18)}}的其他基金

Role of Star Proteins in Bile Acid and Cholesterol Metabolism
星蛋白在胆汁酸和胆固醇代谢中的作用
  • 批准号:
    8096701
  • 财政年份:
    2009
  • 资助金额:
    $ 36.61万
  • 项目类别:
Regulation of Bile Acid Synthesis by Nuclear Receptors in Vivo
体内核受体对胆汁酸合成的调节
  • 批准号:
    7579713
  • 财政年份:
    2009
  • 资助金额:
    $ 36.61万
  • 项目类别:
Role of Star Proteins in Bile Acid and Cholesterol Metabolism
星蛋白在胆汁酸和胆固醇代谢中的作用
  • 批准号:
    8282879
  • 财政年份:
    2009
  • 资助金额:
    $ 36.61万
  • 项目类别:
Regulation of Bile Acid Synthesis by Nuclear Receptors in Vivo
体内核受体对胆汁酸合成的调节
  • 批准号:
    7752527
  • 财政年份:
    2009
  • 资助金额:
    $ 36.61万
  • 项目类别:
Regulation of Bile Acid Synthesis by Nuclear Receptors in Vivo
体内核受体对胆汁酸合成的调节
  • 批准号:
    8207967
  • 财政年份:
    2009
  • 资助金额:
    $ 36.61万
  • 项目类别:
Role of Star Proteins in Bile Acid and Cholesterol Metabolism
星蛋白在胆汁酸和胆固醇代谢中的作用
  • 批准号:
    7866643
  • 财政年份:
    2009
  • 资助金额:
    $ 36.61万
  • 项目类别:
Role of Star Proteins in Bile Acid and Cholesterol Metabolism
星蛋白在胆汁酸和胆固醇代谢中的作用
  • 批准号:
    7738647
  • 财政年份:
    2009
  • 资助金额:
    $ 36.61万
  • 项目类别:
Regulation of Bile Acid Synthesis by Nuclear Receptors in Vivo
体内核受体对胆汁酸合成的调节
  • 批准号:
    8029563
  • 财政年份:
    2009
  • 资助金额:
    $ 36.61万
  • 项目类别:
Regulation of Bile Acid by an alpha 1-AT Peptide
α1-AT 肽对胆汁酸的调节
  • 批准号:
    7080373
  • 财政年份:
    2003
  • 资助金额:
    $ 36.61万
  • 项目类别:
Regulation of Bile Acid by an alpha 1-AT Peptide
α1-AT 肽对胆汁酸的调节
  • 批准号:
    6798146
  • 财政年份:
    2003
  • 资助金额:
    $ 36.61万
  • 项目类别:

相似海外基金

Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
改造甲胎蛋白和磷脂酰肌醇蛋白聚糖 3 以开发肝癌 (HCC) 疫苗
  • 批准号:
    8693488
  • 财政年份:
    2014
  • 资助金额:
    $ 36.61万
  • 项目类别:
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
改造甲胎蛋白和磷脂酰肌醇蛋白聚糖 3 以开发肝癌 (HCC) 疫苗
  • 批准号:
    9231438
  • 财政年份:
    2014
  • 资助金额:
    $ 36.61万
  • 项目类别:
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
改造甲胎蛋白和磷脂酰肌醇蛋白聚糖 3 以开发肝癌 (HCC) 疫苗
  • 批准号:
    8827287
  • 财政年份:
    2014
  • 资助金额:
    $ 36.61万
  • 项目类别:
Suppression of alpha-fetoprotein related hepatocellular proliferation and hepatocellular carcinogenesis in nonalcoholic steatohepatitis
抑制非酒精性脂肪性肝炎中甲胎蛋白相关的肝细胞增殖和肝细胞癌变
  • 批准号:
    24590981
  • 财政年份:
    2012
  • 资助金额:
    $ 36.61万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Induktion einer spezifischen Immunantwort gegen alpha-Fetoprotein mittels AFP-Adenovirus-transfizierter dendritischer Zellen in vitro und in vivo zur Therapie des HCC
使用 AFP 腺病毒转染的树突状细胞在体外和体内诱导针对甲胎蛋白的特异性免疫应答以治疗 HCC
  • 批准号:
    5417539
  • 财政年份:
    2004
  • 资助金额:
    $ 36.61万
  • 项目类别:
    Research Grants
Analysis of alpha-fetoprotein immune responses in patient with hepatocellular carcinoma
肝细胞癌患者甲胎蛋白免疫反应分析
  • 批准号:
    5378445
  • 财政年份:
    2002
  • 资助金额:
    $ 36.61万
  • 项目类别:
    Research Grants
Alpha-Fetoprotein spezifische Immuntherapie des hepatozellulären Karzinoms (C 5)
肝细胞癌(C 5)的甲胎蛋白特异性免疫治疗
  • 批准号:
    5205850
  • 财政年份:
    2000
  • 资助金额:
    $ 36.61万
  • 项目类别:
    Collaborative Research Centres
ALPHA FETOPROTEIN ENHANCERS/LIVER SPECIFIC TRANSCRIPTION
α胎蛋白增强剂/肝脏特异性转录
  • 批准号:
    2487123
  • 财政年份:
    1998
  • 资助金额:
    $ 36.61万
  • 项目类别:
IN VITRO RECONSTITUTION OF ALPHA FETOPROTEIN REGULATION
α 胎蛋白调节的体外重建
  • 批准号:
    6386241
  • 财政年份:
    1997
  • 资助金额:
    $ 36.61万
  • 项目类别:
IN VITRO RECONSTITUTION OF ALPHA FETOPROTEIN REGULATION
α 胎蛋白调节的体外重建
  • 批准号:
    6746481
  • 财政年份:
    1997
  • 资助金额:
    $ 36.61万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了